Northwest Biotherapeutics (NWBO)

Northwest Biotherapeutics (NWBO) Financial Statements


Northwest Biotherapeutics Financial Overview

Northwest Biotherapeutics's market cap is currently ―. The company's EPS TTM is $-0.081; its P/E ratio is -10.45; Northwest Biotherapeutics is scheduled to report earnings on May 16, 2018, and the estimated EPS forecast is $―. See an overview of income statement, balance sheet, and cash flow financials.
Jun 23Mar 23Dec 22Sep 22Jun 22
Income Statement-
Total Revenue$ 201.00K$ 36.00K$ 597.00K$ 206.00K$ 477.00K
Gross Profit$ 201.00K$ 36.00K$ 72.00K--
EBIT$ -13.15M$ -9.63M$ -31.33M$ -31.34M$ -28.24M
EBITDA$ -12.66M$ -9.29M$ -31.01M$ -30.97M$ -27.65M
Net Income Common Stockholders$ -13.93M$ -11.05M$ -32.55M$ -32.85M$ -29.67M
Balance Sheet-
Cash, Cash Equivalents and Short-Term Investments$ 1.42M$ 6.19M$ 6.96M$ 9.43M$ 4.83M
Total Assets$ 28.44M$ 32.87M$ 31.32M$ 31.10M$ 27.52M
Total Debt$ 30.76M$ 31.36M$ 26.25M$ 30.57M$ 31.35M
Net Debt$ 29.33M$ 25.17M$ 19.29M$ 21.15M$ 26.52M
Total Liabilities$ 89.47M$ 65.10M$ 136.37M$ 139.95M$ 119.19M
Stockholders Equity$ -61.03M$ -55.98M$ -128.10M$ -108.85M$ -91.67M
Cash Flow-
Free Cash Flow$ -12.77M$ -12.57M$ -11.01M$ -16.39M$ -15.25M
Operating Cash Flow$ -11.52M$ -11.24M$ -8.85M$ -16.12M$ -14.84M
Investing Cash Flow$ -1.25M$ -1.33M$ -2.16M$ -276.00K$ -408.00K
Financing Cash Flow$ 8.64M$ 12.58M$ 11.35M$ 16.29M$ 10.41M
Currency in USD

Northwest Biotherapeutics Earnings and Revenue History

Northwest Biotherapeutics Debt to Assets

Northwest Biotherapeutics Cash Flow

Northwest Biotherapeutics Forecast EPS vs Actual EPS

What's Included in PREMIUM?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis